With National HealthCare trading at US$176.38, many investors are asking the same question: is the current price justified by the underlying value or has sentiment moved ahead of fundamentals?

The stock has produced returns of 5.9% over the past 7 days, 9.5% over 30 days, 35.3% year to date, 87.7% over 1 year, 228.0% over 3 years and 178.8% over 5 years. This naturally puts a spotlight on what you are paying for each dollar of future cash flow.

Recent coverage has focused on National HealthCare's position within the Healthcare sector and how investors are assessing its role as a long term operator in that space. This context helps frame the recent share price performance as part of a broader conversation around quality, defensiveness and the price investors are currently willing to pay for those attributes.

On Simply Wall St's valuation checks, National HealthCare records a score of 4 out of 6. The next sections will walk through what that means across different valuation approaches and then finish with a way to connect those numbers to a fuller picture of the company.

Approach 1: National HealthCare Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth by projecting future cash flows and then discounting those back to today using a required rate of return. It is essentially asking what those future dollars are worth in current terms.

For National HealthCare, the latest twelve month Free Cash Flow stands at about $149.8 million. Simply Wall St applies a 2 Stage Free Cash Flow to Equity model, using analyst estimates where available and then extrapolating beyond that. In this case, projected Free Cash Flow reaches about $373.4 million in 2035, with interim years such as 2026 and 2027 at $184.0 million and $215.4 million respectively, all in dollar terms.

After discounting each of these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $479.32 per share. Compared with the current share price of $176.38, this implies the stock is 63.2% undervalued based on this DCF framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests National HealthCare is undervalued by 63.2%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: National HealthCare Price vs Earnings

For a profitable company, the P/E ratio is a useful shorthand for what investors are currently paying for each dollar of earnings. It gives you a quick way to compare valuation across businesses that are already generating profits.

What counts as a “normal” or “fair” P/E usually reflects how the market views a company’s growth prospects and risk profile. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk tends to come with a lower P/E.

National HealthCare currently trades on a P/E of 22.93x. That sits close to both the peer group average of 23.48x and the broader Healthcare sector average of about 24.64x. This suggests the market is pricing the stock broadly in line with its sector and listed peers.

Simply Wall St’s “Fair Ratio” takes this a step further. It is a proprietary estimate of what the P/E might be given factors such as earnings growth, profit margins, market cap, industry and company specific risks. Because it blends these inputs, it can be more tailored than a simple comparison with peers or the sector.

In this case, Simply Wall St’s Fair Ratio is not available, so it is not possible to say whether the current 22.93x P/E is above or below that model implied level.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your National HealthCare Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as your way to attach a clear story about National HealthCare to the numbers you care about. This links your view on its future revenue, earnings and margins to a financial forecast, a fair value estimate and then a simple comparison of that fair value with today’s price. All of this is available within an easy tool on Simply Wall St’s Community page that updates when new information like earnings or news is added and that can reflect very different perspectives. For example, one investor might focus on the Community narrative that sets a fair value of about US$179.80 based on assumptions of revenue growth of about 9% and a higher future P/E. Another investor might build a far more cautious narrative with a lower fair value if they place more weight on risks such as margin pressure or regulatory changes.

Do you think there's more to the story for National HealthCare? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.